Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets

17 Nov 2016

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Integrated Circuits and Semiconductor Failure Analysis
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 27866910
DOI: 10.1016/j.chembiol.2016.10.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary TargetsPMID 27866910Read ↗

PARP inhibitors: the story is still unfolding.Semantic proximity Read ↗

PARP inhibitors coming of ageSemantic proximity Read ↗

PARP inhibitors: pitfalls and promises.Semantic proximity Read ↗

Development of PARP inhibitors: an unfinished story.Semantic proximity Read ↗

PARP inhibitors: New partners in the therapy of cancer and inflammatory diseasesSemantic proximity Read ↗

An update on PARP inhibitors—moving to the adjuvant settingSemantic proximity Read ↗

Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell LinesSemantic proximity Read ↗

PARP Inhibition in Cancer: An Update on Clinical DevelopmentSemantic proximity Read ↗

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical ActivitySemantic proximity Read ↗

Understanding and overcoming resistance to PARP inhibitors in cancer therapySemantic proximity Read ↗

The kinase polypharmacology landscape of clinical PARP inhibitorsSemantic proximity Read ↗

Delving into PARP inhibition from bench to bedside and backSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.